🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Dermapharm Holding SE (ETR:DMP)
Germany flag Germany · Delayed Price · Currency is EUR
32.75
-0.70 (-2.09%)
Nov 20, 2026, 5:38 PM CET
← View all transcripts

Earnings Call: Q3 2026

Nov 12, 2026

Summary

9M revenue grew 1.7% to €884 million, with 2.3% organic growth led by branded products; Q3 adjusted EBITDA fell ~€3 million YoY, largely on lower BioNTech contribution. Operating cash flow rose 10%, and FY 2026 guidance was confirmed.

Operator

Ladies and gentlemen, welcome to the Dermapharm Holding SE Q3 2026 results conference call. I am Dobbin, the Chorus Call operator. I would like to remind you that all participants will be in listen-only mode, and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and one on your telephone keypad. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it is my pleasure to hand the call over to Britta Hamberger. Please go ahead.

Britta Hamberger
Head of Investor Relations and Corporate Communications, Dermapharm

Thank you, operator, for the kind introduction. Ladies and gentlemen, welcome to Dermapharm's Q3 2026 webcast, and thank you for joining us today. With me today are our Chief Financial Officer, Christof Dreibholz, and our Chief Marketing Officer, Andreas Eberhorn. Christof and Andreas will guide you through today's presentation. Following the presentation, we will be open for your questions. Andreas, over to you.

Andreas Eberhorn
CMO, Dermapharm

Thanks a lot. Also welcome from my side. In a good tradition, a few words ahead on the commercial side, what's driving our business, and not as a surprise, our branded business segment is driving growth. This is both coming from the German core, from our allergology business, both nationally and internationally, and as well from our international Dermapharm affiliates. Taking a brief look into the German core business, we see a continuous acceleration of our business, especially also the brands where we focus our activities on. This is both in internal sales as well as these brands are performing mostly above their relevant market, which shows that also in the market, the performance is great. As well, another driver are launches, and as you know, with the acquisition of Mucos, we got Wobenzym, which is a great brand and fits nicely in our pain inflammation therapeutic area.

After only three months, we have been able to stabilize the supply of this product and could come quite strong in the market, and this shows really nice growth accelerating month by month. Coming to the allergology business, which is from Allergopharma, one of our companies. Here, both as said in Germany as well as in international businesses, this is a nice growth driver as well. For Germany, and we talked about this already, we managed really to get more than a fair share during this period where brands needed to shift from the market due to some new demands on registration, which we call tough. This is obviously fueling our growth momentum. This is both for the pollen product Allergovit as well as for Novo-Helisen, which is our mite brand. Both of these products developing nicely above the market.

Growth is as well accelerating also in our international affiliates, as I said, not only with the allergology portfolio, but as well with the rest. Based on our strategy, how we want to grow, on the one hand, the portfolio to our existing affiliates. This is both from the existing portfolio within the group as well, obviously, on new developments from our pipeline. We expand to further geographies, adding new affiliates where we launch as well our portfolio, and expanding also our distributor networks internationally. Here, especially Poland, Spain, and China are sticking out in terms of growth. If we come to the segment of other healthcare business, this is slightly lagging behind.

On Arkopharma, the strategic shift we did moved the business towards B2B2C with the pharmacist in the center and a massive ramp-up and invest also in innovations and a new look and feel of Arkopharma develops as expected, and especially here with very nice developments we see in Spain and Italy. Euromed is as well doing nicely. Our growth comes mainly from European and Asian customers, with still being on the product level. Our cannabis business, Candoro ethics, and as well our business, Hübner, with food supplements in Germany, they both are facing some challenging market conditions at the moment. On the Candoro side, there was this new law issued, we call—

[Non-English content]

—not easy to translate, but I think you know it, which is there to compensate for accelerating health insurance costs.

This had an impact on the use of our main product, dronabinol, as well as some extracts. This part has been corrected in the law, so further impact should be limited and as well, but this is continuously here, this market is as well under price pressure from the payer side. On Hübner, as well a regulatory topic for a big part of our international business with China. There are new regulations which impose for us a shift how we do cross-border activities and online marketing. As well in the German market, there's, in this food supplement business, price pressure and strong competition we need to deal with. Important to say is, given the size of both companies, and the impact is not really material and is compensated by other parts of the company.

Finally, on our parallel import business, we are continuously working on optimizing the portfolio as we shared with the new strategy, and the effects Christof Dreibholz will share later in this part. So this was from my side, brief view, what is driving our business, and with that, I hand over to Christof Dreibholz.

Christof Dreibholz
CFO, Dermapharm

Thank you, Andreas. I will continue and give you an update on latest developments regarding the Mucos acquisition. In line with the closing accounts mechanism stipulated in the SPA, we have agreed the final purchase price with Nestlé. Beginning of October 2026, so after the nine-month period we are currently looking at, the final consideration of approximately EUR 34 million, including interest, after having made an initial payment of EUR 33 million at the beginning, by the end of December 2025, i.e., in total EUR 67 million. The final payment beginning of October 2026 comprised a profit transfer receivable of Mucos, which had before been settled in cash by Nestlé.

The resulting preliminary badwill is roughly EUR 24 million. It is still preliminary as the purchase price allocation has not been finalized yet. The release to income of this is shown as other non-cash income and is adjusted at normalized EBITDA level.

If we look at the Q3 figures of the group summarized on this slide five, net sales are approximately at prior year level. Branded products revenues increase mostly inorganically, whilst other healthcare products revenue slightly decline compared to Q3 2025. As Andreas explained, many drivers or main drivers are seasonal, regulatory impacts, and the lower demand due to a lower purchasing power of consumers. Despite these adverse external factors, Arkopharma, among other, did well with revenues at prior year level and an improved EBITDA compared to prior year Q3. Q3 adjusted EBITDA is approximately EUR 3 million behind prior year. Main reason for this is a correspondingly lower contribution from BioNTech. Operationally, the branded product segment compensated for a slightly lower performance of the other two segments. Having mentioned BioNTech, and we haven't spoken about that over the last quarters, the total contribution from BioNTech is still minor.

However, looking in an isolated way only at Q3, there was a change of EUR 3 million in that quarter. Earnings after tax decline as a consequence of the slightly lower EBITDA and above average depreciation charges in relation to development projects that have been canceled and the initial consolidation of Mucos. Slide six, please. The nine-month year-to-date performance summarized on this slide shows a revenue increase by 1.7% to EUR 884 million. The growth is attributable to the initial consolidation of the acquired entities, Mucos and Trenker, as well as the organic growth of the German core and the international businesses of the branded segment. The organic growth rate was 2.3% in the nine months 2026. This growth was partially compensated by lower parallel import revenues following the portfolio optimization. The moderate decline of other healthcare revenues has been attributable to seasonal regulatory and purchasing power-related impacts.

EBITDA and EBITDA margin growth is primarily driven by the high-margin branded product segment and, to a lesser extent, also the other healthcare segment. Earnings after tax are approximately at prior year level, as the release of the preliminary badwill to income and the write-down of the financial receivable largely offset each other. The favorable operating performance at EBITDA level in the nine months 2026 drives the growth of the operating cash flow to approximately EUR 149 million, + 10% compared to the prior year nine months. The operating cash flow is not impacted by the non-cash, non-operational income from the Mucos purchase price allocation, the impairment of the financial receivable, and the balance sheet-related share buyback. Slide seven, please. We bridge key elements of nine months 2026 performance, leaving earnings after tax slightly below prior year.

Whilst other healthcare and parallel import are approximately at prior year level, the domestic and international businesses within branded products drive the operational growth at results level. The net impact from the impairment of the financial receivable, i.e., EUR 30 million, and the change in adjustments to EBITDA, EUR 24.1 million, is approximately EUR 6 million. The major amount as part of the adjustments is obviously the release to income in connection with the Mucos purchase price allocation. Interest cost, mainly for the syndicated loan, declined following the covenant improvement, leading to a lower margin according to the underlying margin grid on top of the EURIBOR compared to last year. The interest rate hedging terminated end of 2025. CIT and trade tax payments also decline in the nine months 2026, as previous periods have been impacted by payments for prior years.

Depreciation charges increased by EUR 13 million, largely as a consequence of above-average depreciation charges in relation to development projects that have been canceled. Slide eight, please. The normalization. EBITDA normalization mainly comprised the reversal of the preliminary income from the release of the PPA tool, as mentioned before. Other adjustments are in total EUR 4.9 million, mainly resulting from restructuring, EUR 1.8 million, largely at Arko and Mucos, and the reduction of inventories due to the destruction of a warehouse in the Ukraine, another EUR 1.8 million.

Other exceptional items of EUR 1.3 million in total comprise M&A-related cost expenses in relation to the share buyback and other smaller items. Slide nine. The strong operating performance and the declining financing cost lift the interest cover to 2x . Net financial debt increases compared to March [2026] as a result of the share buyback executed in Q2. Current leverage is 3.1x adjusted EBITDA.

We currently foresee the leverage to be below 3x adjusted EBITDA by the end of 2026. The equity ratio increased percentage points in Q3 to roughly 26% as of September [inaudible] as a result of the Q3 earnings. Slide 10. Our balance sheet total is largely unchanged compared to December 2025 due to a combination of operational working capital-related impacts and non-operational effects. Non-current and current assets are impacted by the initial consolidation of Mucos. Additionally, current assets increase from higher inventories and trade receivables. This increase is offset by reduced liquid funds, largely due to the execution of the share buyback program, and a reduced advance payment receivable, the latter due to the settlement of the initial purchase price payment before year-end 2025. That is the EUR 33 million I mentioned in the beginning. Non-current assets also increase from the first-time consolidation of Mucos.

However, the impact is offset by the impairment of the long-term financial receivable recorded in Q2. The equity figure has been impacted by the cancellation of the shares that have been acquired as part of the share buyback, roughly EUR 100 million, the dividend payment in July, EUR 44 million, and the earnings after tax generated in the year-to-date September 2026 period, approximately EUR 90 million. Non-current liabilities are higher following the contracted new financing in connection with the share buyback, net of the scheduled half-year amortization payment of our SSD loan. Current liabilities have mainly been impacted by the recognition of the remaining Mucos purchase price obligation, settled at the beginning of October 2026. Net working capital is approximately 13% higher than the level seen as of September 2025. The underlying cash cycle increases by 10% to 86 days.

Whilst the underlying growth in the branded product segment partially explains this development, we observe, however, a growing net working capital across the business. Higher inventories are mainly driven by growing raw materials, half of the increase resulting from seasonal impacts from the harvesting period regarding Euromed raw materials. DIO is 180 days, and hence five days or 4% above the year-to-date June 2026 level. Higher trade receivables are observed across the group. DSO increases by three days to 44 days, two days above the level observed in the first half of 2026. The increase represents an 8% growth compared to year-to-date September 2025 and is hence above the average sales growth in the same period. However, no specific unusual payment difficulties of customers are currently observed.

The nine months 2026 show a 10% increase in the cash flow from operating activities compared to prior year, underlining the good operational performance of the business. Main contributors are the underlying EBITDA improvements, driven once again by the branded product segment and sustainably lower tax payments. CapEx is largely changed, higher investment in tangible and intangible as executed in the nine months 2026, whereas the nine months 2025 saw the investment at equity participation. Recurring CapEx is approximately EUR 39 million, and hence EUR 9 million higher than prior year. Free cash flow increases by 17%. Cash conversion is approximately 60% of adjusted EBITDA, nearly 3 percentage points ahead of prior year. Details of the improved operating cash flow are shown on the next slide, 13.

Along with the improved cash EBITDA, operating cash flow is mainly impacted by cash outflows from a buildup of working capital, as mentioned before, more than compensated by sustainably lower tax payments, as prior years burdened by tax payments related to historical financial years, especially 2022 and 2023. With that, I am to the outlook. Based on the nine-month results and the scheduled reforecast, we confirm the guidance for 2026. Growth in branded products is expected to continue, driven by existing portfolio and further expansion, seasonal demand for anti-allergy products, and international growth. No material impact from the German Financial Stabilization Act anticipated in 2026. Other healthcare revenues and PI gross margin are expected to be slightly below prior year and will be compensated by branded pharmaceutical performance. Thank you.

Britta Hamberger
Head of Investor Relations and Corporate Communications, Dermapharm

Thank you, Christof. Now we can open the line for questions, please.

Operator

We will now begin the question-and-answer session. Anyone who wishes to ask a question may press star and one on their touch-tone telephone. You will hear a tone to confirm that you have entered the queue. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use only handsets while asking a question. Anyone who has a question may press star and one at this time. The first question comes from the line of Christian Ehmann with Berenberg. Please go ahead.

Christian Ehmann
Analyst, Berenberg

Hello, everyone. Thanks for taking my question. I have two, please. Could you please give us an update on the current state of the BaFin investigation? The second one would be in regard to the Arkopharma improvement in France especially. Could you give us an update or remind us of the timeline you expect here to see material improvements? Thank you very much.

Christof Dreibholz
CFO, Dermapharm

I will take the BaFin question. Thank you. We expect BaFin to publish its decision shortly, which will bring this matter to a close. We are confident that it will have no material impact on our financial position, our results of operations, or our guidance. Please understand that we will not comment further before the publication.

Andreas Eberhorn
CMO, Dermapharm

Well, on Arkopharma, you mentioned specifically France. We had growing market shares in France during summer, which shows that we are on the right track. This is not a sprint, this is a marathon. Improvements will be seen and have impact step by step. We have very strong customer feedbacks sharing their view that Arkopharma increasingly changed the way they act, being now a real partner, which ultimately is translating and will further translate into sales. This year is robust. Next year, we expect further accelerations as planned. This we see both from the feedback from customers as well as already pre-orders we are getting. This is in sum a very good and positive trend. We back this with a lot of media campaigns being active outside, and as well as boosting 2027 with a big acceleration also in new innovations.

And obviously, France as the biggest market will profit the most here.

Christian Ehmann
Analyst, Berenberg

Thank you very much. Very helpful.

Operator

Thank you. Once again, if you wish to register for a question, please press star then one. There are no more questions at this time. Apologies. We have a question from the line of Miro Zuzak with JMS Invest AG. Please go ahead.

Miro Zuzak
Analyst, JMS Invest AG

Yes, hello. Thank you for taking my question. Can you hear me?

Britta Hamberger
Head of Investor Relations and Corporate Communications, Dermapharm

Yes, we can hear you.

Miro Zuzak
Analyst, JMS Invest AG

Okay. Please apologize. I was just a couple of minutes late in the beginning of the call. If you have already answered it, please kick me out or answer it again, please. I haven't been here in the first couple of minutes. The question is on the top line of branded pharmaceuticals. Obviously, the performance was very strong in H1, especially also Q2, against a tougher base in Q2 last year compared to Q1. It seems like this has completely come to a halt with this very modest growth. Can you please explain again what happened exactly in the quarter? How much of the weak performance was kind of one-off effect? How much was maybe driven also by the nice weather? What actually happened there? You mentioned BioNTech, I'm aware of that. You mentioned the extent was EUR 3 million, but maybe that doesn't explain everything, right?

Christof Dreibholz
CFO, Dermapharm

I mean, I can briefly start just from the numbers. If I look in the quarter and look at branded is indeed increasing. It's not coming, I wouldn't say it is coming to a halt.

Miro Zuzak
Analyst, JMS Invest AG

If you compare, it's increasing versus last. The increase is 1.7%, right? Versus 2025 Q3. EUR 164 million versus EUR 161 million. If I look in Q2, it was EUR 159 million versus EUR 142 million. So the increase was almost 12% in Q2, almost 12% in Q1.

Christof Dreibholz
CFO, Dermapharm

Yes.

Miro Zuzak
Analyst, JMS Invest AG

Obviously, now it is +1.7% instead of 12%.

Christof Dreibholz
CFO, Dermapharm

Yeah.

Miro Zuzak
Analyst, JMS Invest AG

I think this needs some explanation. Of course, it was up incrementally and also year-on-year, but it was up not by 12% but by 1.7%.

Christof Dreibholz
CFO, Dermapharm

Yeah. We are looking at each other. There is nothing specific that we could mention, just thinking of the German core or allergology business. Nothing where we see any specific impacts currently. We can try to look into this a little deeper and then answer afterwards.

Britta Hamberger
Head of Investor Relations and Corporate Communications, Dermapharm

We can make an analysis for single entities, yeah.

Christof Dreibholz
CFO, Dermapharm

Yeah. If that helps, but just from our perspective, there is nothing exceptional, for example, that has happened in Q3, especially in branded, that jumps to our mind.

Miro Zuzak
Analyst, JMS Invest AG

Okay. Thank you.

Operator

The next question comes from the line of Nico Löchner with Solventis. Please go ahead.

Nico Löchner
Analyst, Solventis

Yes, hello. Good afternoon. I basically had the same question as the last person who asked it. If you look at it organically, it is a decline even with the Mucos acquisition. Is it right or do I calculate it wrong?

Christof Dreibholz
CFO, Dermapharm

Yeah, that is correct.

Nico Löchner
Analyst, Solventis

So it would be good to know later what were the reasons for the decline. Or what are the moving parts between Q2 and Q3, what did not grow anymore?

Christof Dreibholz
CFO, Dermapharm

Yeah. Yeah, we will look at it. Most likely it is phasing, but we will look into it.

Operator

Nico Löchner, does that answer your question? Do you have any further questions?

Nico Löchner
Analyst, Solventis

Yeah, it basically answered. Could you give us a small outlook for Q4 then? Do you expect an acceleration in the growth for branded then again?

Christof Dreibholz
CFO, Dermapharm

I mean, we gave you the outlook on our last slide, so we confirm the guidance. In that is correspondingly also a contribution from branded products to achieve that.

Nico Löchner
Analyst, Solventis

Okay, thank you.

Operator

Our next question comes from the line of Miro Zuzak with JMS Invest AG. Please go ahead.

Miro Zuzak
Analyst, JMS Invest AG

Yes, hi again. Thank you for taking my question. I have a question regarding the structures which are in place to monitor the different business lines. How do you do that within the company? If you have your businesses, the companies reporting to you, have you defined KPIs? Do you have a management dashboard showing you the performance of the business? Do you have, for example, a green, amber, red panel where you can see, okay, this business is performing worse compared to expectations? How is that done within your company?

Christof Dreibholz
CFO, Dermapharm

We look at the segments. That's the main driver that we are analyzing. Then, of course, we have also then a next level in order to understand what is actually happening and where is it happening, i.e., we also see then below that legal entities or, for example, in regard to the international or the German core business, a summary of the underlying businesses. There we see prior year, we see the current year, and we see budget.

Miro Zuzak
Analyst, JMS Invest AG

As a follow-up, if you look at this dashboard now with what you just said, I mean, what do you see? How many businesses are on track? Green, basically, how many businesses have question marks? How many businesses do not outperform their budget or the expectations? Which ones are they?

Christof Dreibholz
CFO, Dermapharm

We have that. Here we report at segment level, and I cannot give you a number of legal entities. In, for example, in branded, it's condensed to three subgroups, i.e., what I mentioned before, the international, the domestic, and the allergology business, and they are all on track. The other healthcare segment is a summary of different entities, and I apologize, I don't have it in the top of my mind the number of entities that is performing well, bad, or on average. PI is the end, PI segment is the end, axicorp. So it's one entity, one major entity.

Miro Zuzak
Analyst, JMS Invest AG

Okay. Thank you.

Operator

Thank you. Ladies and gentlemen, that was the last question. I would now like to turn the conference back over to Britta Hamberger for a closing remark.

Britta Hamberger
Head of Investor Relations and Corporate Communications, Dermapharm

Thank you very much for your questions. If there are any questions left open, we can pick it up later on. I will be available at 5:30 P.M. after this call. Thank you.

Operator

Ladies and gentlemen, the conference is now over. Thank you for choosing Chorus Call, and thank you for participating in the conference. You may now disconnect your lines. Goodbye.